Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Loading...
Embargo End Date
ICR Authors
Authors
Davies, FE
Pawlyn, C
Usmani, SZ
San-Miguel, JF
Einsele, H
Boyle, EM
Corre, J
Auclair, D
Cho, HJ
Lonial, S
Sonneveld, P
Stewart, AK
Bergsagel, PL
Kaiser, MF
Weisel, K
Keats, JJ
Mikhael, JR
Morgan, KE
Ghobrial, IM
Orlowski, RZ
Landgren, CO
Gay, F
Caers, J
Chng, WJ
Chari, A
Walker, BA
Kumar, SK
Costa, LJ
Anderson, KC
Morgan, GJ
Pawlyn, C
Usmani, SZ
San-Miguel, JF
Einsele, H
Boyle, EM
Corre, J
Auclair, D
Cho, HJ
Lonial, S
Sonneveld, P
Stewart, AK
Bergsagel, PL
Kaiser, MF
Weisel, K
Keats, JJ
Mikhael, JR
Morgan, KE
Ghobrial, IM
Orlowski, RZ
Landgren, CO
Gay, F
Caers, J
Chng, WJ
Chari, A
Walker, BA
Kumar, SK
Costa, LJ
Anderson, KC
Morgan, GJ
Document Type
Journal Article
Date
2022-07-06
Date Accepted
2022-07-01
Abstract
The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
Citation
Blood Cancer Discov, 2022, 3 (4), pp. 273 - 284
Source Title
Blood Cancer Discov
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
2643-3230
eISSN
2643-3249
2643-3249
2643-3249
Collections
Research Team
Myeloma Biol Therap
Myeloma Molecular Therapy
Myeloma Molecular Therapy